Olaparib is a targeted anti-cancer medication classified as a PARP inhibitor, primarily used for treating various cancers, including ovarian, breast, pancreatic, and prostate cancers. It is particularly effective in patients with BRCA mutations, as it exploits the cancer cells' reliance on PARP for DNA repair. By inhibiting PARP, Olaparib induces synthetic lethality in these cancer cells, leading to their death. In summary, Olaparib represents a significant advancement in personalized cancer therapy, especially for patients with specific genetic backgrounds.
Olaparib inhibits poly(ADP-ribose) polymerase (PARP), disrupting the DNA repair process in cancer cells, particularly those deficient in homologous recombination repair, leading to cell death.
No published brands for this salt yet.